Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition

Pharmaceutical Market News and Data: India’s Drug Market Grows 17.1% in September 2026 as Global Pharma Companies Accelerate Innovation, Capacity Expansion and Strategic Deals a study by Towards Healthcare

Ottawa, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The global pharmaceutical market to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 at a 6.15% CAGR, while India’s pharmaceutical market recorded 17.1% year-over-year growth, highlighting the expanding opportunities in innovative medicines, generics, biologics, advanced manufacturing, and global market expansion a study by Towards Healthcare sister firm of Precedence Research.

Fill out the form for relevant samples, case studies, and examples @ https://www.towardshealthcare.com/download-sample/5341

The global pharmaceutical market is entering a period of strategic transformation as demand for medicines expands alongside investment in biologics, specialty drugs, oncology treatments, advanced therapies, and AI-enabled drug development. At the same time, pharmaceutical companies are reassessing manufacturing locations, international market exposure, pricing strategies, and portfolio priorities in response to regulatory changes and evolving healthcare demand.

Recent industry developments add important context to this forecast. India’s pharmaceutical market recorded 17.1% year-over-year growth in September 2026, while pharmaceutical companies continue to pursue high-value product development, manufacturing expansion, licensing agreements, and technology partnerships. These developments indicate that future growth will depend not only on overall demand but also on companies’ ability to differentiate their portfolios, improve operational resilience, and identify attractive markets.

Pharmaceutical Market Data Snapshot

Market Indicator	Data		Business Implication
Global market size, 2025	USD 1,772.65 billion		Establishes a substantial global commercial base
Global market size, 2026	USD 1,881.67 billion		Indicates continued expansion in pharmaceutical demand
Forecast market size, 2035	USD 3,219.76 billion		Supports long-term investment and portfolio planning
CAGR, 2026–2035	6.15	%	Provides a benchmark for strategic growth planning
North America share, 2025	36	%	Maintains the region’s position as the largest regional market
Branded medicines share, 2025	70	%	Highlights the commercial importance of established and innovative brands
Prescription medicines share, 2025	75	%	Reinforces the importance of prescription-focused portfolios
Cancer medicines share, 2025	30	%	Demonstrates the significance of oncology in pharmaceutical revenues
Oral medicines share, 2025	50	%	Highlights the commercial importance of oral formulations
India pharmaceutical market growth, September 2026	17.1% year over year		Signals strong near-term demand and volume opportunities

Source for global market estimates: Towards Healthcare Pharmaceutical Market Research. India’s September growth reflects reported domestic industry performance.

What the Latest Market Data Indicates

The projected increase from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 represents an expansion of approximately USD 1.34 trillion in annual market value over the forecast period. This creates opportunities across drug development, manufacturing, contract services, distribution, and commercialization.

However, the growth opportunity is not evenly distributed. Pharmaceutical companies must distinguish between established high-revenue categories and faster-evolving opportunities in biologics, biosimilars, precision medicine, specialty treatments, and advanced drug delivery.

Three strategic conclusions emerge from the market outlook:

• Portfolio diversification is becoming increasingly important as companies balance established brands, generics, and innovative medicines.
• Regional prioritization requires more than comparing market size; pricing, reimbursement, regulation, manufacturing access, and competition also determine commercial attractiveness.
• Competitive intelligence must increasingly connect product pipelines, market launches, investment activity, capacity, and customer demand.
  

Schedule a meeting: Book a Meeting with the Expert Team

Segment and Regional Intelligence

Segment	Market Position	Strategic Opportunity
Conventional drugs	50% share in 2025	Scale, cost efficiency, product lifecycle management, and established demand
Branded medicines	70% share in 2025	Brand differentiation, commercial execution, and portfolio expansion
Generic medicines	Expected to grow over the forecast period	Affordable treatment access, complex generics, and international market entry
Prescription medicines	75% share in 2025	Specialty sales, physician engagement, and patient-access strategies
Oncology	30% share in 2025	Targeted therapies, biologics, and differentiated treatment portfolios
Oral medicines	50% share in 2025	Formulation development, convenience, and broader patient access
Parenteral medicines	Projected fastest-growing administration route	Injectable biologics, specialty therapies, and sterile manufacturing
Clinics	Projected fastest-growing end-user segment	Outpatient treatment, specialty care, and distribution partnerships

North America accounted for 36% of the global pharmaceutical market in 2025. The region benefits from substantial healthcare expenditure, advanced research infrastructure, established pharmaceutical commercialization networks, and demand for innovative therapies.

Asia Pacific is projected to grow faster than the global market, with a forecast CAGR of 7.02% through 2034. China’s pharmaceutical market is projected to increase from USD 93.11 billion in 2026 to USD 183.66 billion by 2035, representing a 7.84% CAGR.

These regional differences create distinct priorities. North America remains important for commercialization, product differentiation, and specialty medicines, while Asia Pacific presents opportunities in manufacturing, generics, biosimilars, healthcare access, and localized product strategies. Companies expanding internationally need country-level assessments that consider market potential alongside regulatory requirements, competition, pricing, and distribution.

Latest Pharmaceutical Industry News and Company Developments

India’s pharmaceutical market records strong growth

India’s pharmaceutical market grew 17.1% year over year in September 2026, with sales reaching approximately ₹253 billion. Unit growth reached 5.4%, indicating that increased sales were supported by higher volumes rather than price increases alone.

The second quarter of fiscal 2027 recorded sales of approximately ₹746.1 billion, representing 14.7% year-over-year growth. Oncology recorded 29.4% growth, while vitamins, minerals and nutritionals increased 22.2%, anti-diabetic medicines grew 21.2%, and cardiac therapies increased 20.4%.

This performance creates opportunities for domestic manufacturers, distributors, and international companies evaluating India. It also reinforces the importance of therapy-level demand analysis, competitor benchmarking, and product prioritization rather than relying exclusively on aggregate market growth.

Biocon advances its oncology commercialization strategy

Biocon has finalized a global settlement and licensing agreement with Genentech concerning its cancer medicine Pebrilzo. The agreement resolves ongoing legal disputes and establishes a pathway for planned launches in different markets, subject to regulatory approvals. European Union and UK launches are targeted for early 2027, with a US launch planned for the third quarter of 2028.

The development highlights how intellectual property agreements, licensing arrangements, and launch timelines can influence the commercial value of pharmaceutical assets. Companies evaluating oncology portfolios should monitor legal status, geographic rights, approval requirements, launch readiness, and competitive positioning.

AI-driven drug discovery attracts major investment

On October 13, 2026, Zealand Pharma and Generate Biomedicines announced a collaboration to develop AI-designed protein treatments for obesity and metabolic diseases. The agreement is valued at up to USD 1.2 billion, including an initial USD 30 million payment and potential milestone payments linked to development progress.

The partnership illustrates how pharmaceutical innovation is increasingly shaped by collaboration between established drug developers and technology-focused biotechnology companies. AI-enabled discovery is creating opportunities in target identification, molecule design, candidate selection, and development prioritization, although clinical success and regulatory approval remain uncertain.

For pharmaceutical decision-makers, the commercial question is not simply whether a company uses AI, but whether its technology produces differentiated candidates, credible clinical evidence, scalable manufacturing, and a viable route to commercialization.

Manufacturing investment becomes a strategic priority

Pharmaceutical companies are continuing to invest in domestic production, specialized manufacturing, and supply-chain resilience. In India, Aragen Life Sciences began operations at a high-potency manufacturing platform in Hyderabad in October 2026. The 15,000-square-foot facility has an annual production capacity of 500–600 kg of active pharmaceutical ingredients.

Separately, Zydus Sunshine Lifesciences announced a USD 20 million agreement associated with a pharmaceutical plant in Sri Lanka, with its first phase focused on oral solid dosage forms for the local market.

These developments highlight opportunities for contract manufacturers, suppliers, equipment providers, and pharmaceutical companies seeking regional production capabilities. Facility intelligence, production capacity, technology capabilities, customer relationships, and expansion plans are becoming essential inputs for procurement and investment decisions.

Regulatory developments increase the importance of compliance intelligence

Pharmaceutical companies must also monitor changes in product approvals, manufacturing inspections, pricing policy, marketing practices, and regulatory oversight.

In India, recent developments have included scrutiny of pharmaceutical marketing practices and consideration of tighter oversight for sterile drug products. Such developments can affect compliance obligations, commercialization practices, and manufacturing requirements.

Companies operating across multiple countries need structured regulatory intelligence to anticipate changes, assess potential operational impacts, and prioritize compliance activities.

Where the Pharmaceutical Market Opportunity Is Emerging

The strongest opportunities are increasingly found at the intersection of product innovation, manufacturing capability, and market access.

• Biologics and biosimilars: Growing demand for targeted therapies and affordable alternatives creates opportunities in development, manufacturing, licensing, and commercialization.
• Oncology and specialty medicines: High-value treatment categories create opportunities for differentiated products, pipeline evaluation, and market-access planning.
• AI-enabled pharmaceutical research: Partnerships and technology investments can support faster candidate discovery and more targeted research strategies.
• Complex generics and advanced formulations: Manufacturers can pursue higher-value products requiring specialized capabilities and regulatory expertise.
• Asia Pacific market expansion: China, India, and other regional markets offer opportunities that require country-specific demand and competitive analysis.
• Contract development and manufacturing: Companies can evaluate new customers, facility utilization, production technologies, and outsourcing opportunities.
• Portfolio and licensing opportunities: Patent developments, licensing agreements, acquisitions, and partnerships can change the commercial outlook for individual products.
  

Companies should also account for pricing pressure, regulatory uncertainty, supply-chain concentration, clinical-development risk, and competitive launches. Market growth does not guarantee that every product, company, or geographic expansion will generate attractive returns.

How Towards Healthcare Helps Pharmaceutical Companies Make Better Decisions

Towards Healthcare Research & Consulting provides market-specific research and intelligence to support pharmaceutical manufacturers, biotechnology companies, contract development and manufacturing organizations, investors, distributors, and commercial strategy teams.

Towards Healthcare Solution	What the Client Receives	Pharmaceutical Market Application
Master Dataset	Structured company, product, therapy, country, supplier, facility, capacity, investment, partnership, and launch information	Supports market mapping, sales targeting, sourcing, competitor tracking, and business development
Towards Healthcare Quadrant	Company benchmarking, portfolio comparisons, capability assessment, and competitive positioning	Identifies market leaders, emerging competitors, capability gaps, and potential partnership targets
Interactive Dashboard	Organized indicators covering companies, segments, countries, products, investments, technologies, and industry developments	Helps teams monitor changes without repeatedly rebuilding static research reports
Quality & Manufacturing Intelligence	Facility locations, production capabilities, capacity, manufacturing technologies, suppliers, expansion plans, and operational developments	Supports procurement, capacity planning, supplier assessment, manufacturing strategy, and supply-chain risk management
Customized Research	Market-entry studies, demand analysis, pricing research, customer intelligence, company profiles, M&A assessments, and GTM strategy	Supports investment decisions, geographic expansion, product launches, portfolio strategy, and commercialization

Master Dataset and Competitive Intelligence

Pharmaceutical-specific datasets can connect companies with their products, therapeutic categories, manufacturing sites, suppliers, geographic presence, partnerships, investments, and commercial developments.

Sales teams can identify prospective customers and partners. Business development teams can map licensing and acquisition opportunities. Strategy teams can compare competitors by portfolio, capabilities, and regional presence. Procurement teams can identify potential suppliers and evaluate manufacturing footprints.

Towards Healthcare Quadrant and Interactive Dashboard

The Towards Healthcare Quadrant can support structured benchmarking of pharmaceutical companies across portfolio breadth, therapeutic focus, geographic reach, manufacturing capabilities, and innovation activity.

The interactive dashboard complements this analysis by helping decision-makers monitor market developments, competitive moves, investments, product launches, and technology changes. Together, these tools can support ongoing strategic reviews and help teams identify shifts that may require action.

Quality & Manufacturing Intelligence

Manufacturing intelligence can cover plant locations, capacity, production technologies, suppliers, operational developments, expansion plans, and relevant quality and regulatory indicators.

This is especially useful for manufacturers evaluating new facilities, CDMOs assessing potential customers, procurement teams diversifying supply, and investors comparing operational capabilities. Customized research can also address market entry, pricing, demand forecasting, supplier mapping, strategic benchmarking, and M&A opportunities.

Continuously Updated Pharmaceutical Market Intelligence

Intelligence can be maintained according to client requirements through monthly, quarterly, six-monthly, or annual updates.

Monthly updates may capture product launches, company announcements, investments, regulatory developments, clinical milestones, pricing changes, and capacity expansions. Quarterly updates can support management reviews and competitive planning, while six-monthly and annual updates can support long-term portfolio strategy, market entry, investment assessment, and manufacturing decisions.

The appropriate frequency depends on the market, product lifecycle, competitive intensity, and decisions the client needs to make.

Access Pharmaceutical Market Research and Intelligence

Explore Towards Healthcare’s pharmaceutical market research for detailed forecasts, segment analysis, regional assessments, and competitive insights.

• Download a sample: Request the Pharmaceutical Market Report Sample
• Buy the report: View Report Options and Proceed to Checkout
• Access dashboard services: Access the Towards Healthcare Dashboard
• Email: sales@towardshealthcare.com

Related Reports

1. Pharmaceutical Manufacturing Market - Manufacturing capacity, technology, and production outlook.
2. Biologics Market - Biologic medicines, product segments, and growth opportunities.
3. Biosimilars Market - Biosimilar competition and access opportunities.
4. Generic Drugs Market - Generic medicine demand and competitive trends.
5. Oncology Market - Cancer treatment demand and therapeutic developments.
6. Cancer Biologics Market - Biologic oncology treatments and market opportunities.
7. AI in Pharmaceuticals Market - AI adoption across drug discovery and development.
8. U.S. Pharmaceutical Market - U.S. market outlook and competitive landscape.
9. North America Pharmaceutical Market - Regional demand, innovation, and investment trends.
10. Pharmaceutical Market Intelligence and Research - Global market forecasts and segment-level analysis.

Partner

• Precedence Research
• Towards Packaging
• Towards Chemical & Materials
  

Connect With Us

USA: +1 804 441 9344

APAC: +61 485 981 310 | +91 87933 22019 | +65 3105 1271

Europe: +44 7383 092 044

Email: sales@towardshealthcare.com

Follow Towards Healthcare

• LinkedIn
• X
• Instagram